WO2012090218A4 - Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases - Google Patents

Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases Download PDF

Info

Publication number
WO2012090218A4
WO2012090218A4 PCT/IN2011/000867 IN2011000867W WO2012090218A4 WO 2012090218 A4 WO2012090218 A4 WO 2012090218A4 IN 2011000867 W IN2011000867 W IN 2011000867W WO 2012090218 A4 WO2012090218 A4 WO 2012090218A4
Authority
WO
WIPO (PCT)
Prior art keywords
combination
amended
concentration
paracetamol
specific compound
Prior art date
Application number
PCT/IN2011/000867
Other languages
French (fr)
Other versions
WO2012090218A1 (en
Inventor
Kamlesh Rajnikant Zota
Sanjay Agrawal
Ketan Chandulal Zota
Manukant Chandulal Zota
Himanshu Muktilal Zota
Original Assignee
Zota Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zota Health Care Ltd filed Critical Zota Health Care Ltd
Publication of WO2012090218A1 publication Critical patent/WO2012090218A1/en
Publication of WO2012090218A4 publication Critical patent/WO2012090218A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

This invention is based on efficacy of compounds and combination of compounds. Which essential for treatment of a number of diseases. These are pain, antiinfilamation, hepatoprotective, fever, allergy thereof. This combination has less toxicity, it has highly hepatotoxicity. The main mechanism of action of paracetamol is considered to be the inhibition of cyclooxygenase (COX) that it is highly selective for COX-2. The concentration of paracetamol is 500mg and thereof. Racemethionine is anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. The concentration of racemethionine is 50mg and thereof. All effective cold remedies containing phenylephrine. The concentration of Phenylephrine is 5 mg/tablet and thereof. Phenylephrine to form an allergy medication with both antihistamine and decongestant properties. Chlorphenaminemaleate is suitable compound for cough and cold.chlorphenamine maleate to form an allergy medication with both antihistamine and decongestant properties. The concentration of chlorphenaminemaleate is 2 mg/tablet and thereof. Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis. The concentration of caffeine is 15 mg/tablet and thereof.

Claims

AMENDED CLAIMS
received by the International Bureau on 25 June 2012 (25.06.2012)
AMENDED SHEET (ARTICLE 19)
1) (Cancelled)
2) (Amended) Synergistic effects of the combination of the specific compound comprises of paracetamol, racemethionine, caffeine, chlorpheniramine maleate and Phenylephrine in variable quantities.
3) (Amended) Synergistic effect of the combination of the specific compound is claimed as claim 2 wherein said these are pain, antiinfilamation, hepatoprotective, fever, allergy thereof. This combination has less toxicity.
4) (Amended) Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said the mechanism of paracetamol is that inhibition of cyclooxygenase (COX), and recent findings suggest that it is highly selective for COX-2. It's selectivity for COX-2 it does not significantly inhibit the production of the pro-clotting thromboxanes. The concentration of paracetamol is 500mg and thereof.
5) (Amended) Synergistic effects of the combination of the specific compound is claimed as claim 2 wherein said Racemethionine is anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. It protects hepatocytes and enhances their regeneration thus improving liver function. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. It protects hepatocytes and enhances their regeneration thus improving liver function. The concentration of racemethionine is 50mg and thereof.
6) (Amended) Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said all effective cold remedies containing phenylephrine. The concentration of Phenylephrine is 5 mg/tablet and thereof. Phenylephrine to form an allergy medication with both antihistamine and decongestant properties. 7) (Amended) Synergistic effects of the combination of the specific compound is claimed as claim 2 wherein said Chlorphenamine maleate is suitable compound for cough and cold chlorphenamine maleate to form an allergy medication with both antihistamine and decongestant properties. The concentration of chlorphenamine maleate is 2 mg. /tablet and thereof.
8) (Amended) Synergistic effects of the combination of the specific compound are claimed as claim 2 wherein said Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis. The concentration of caffeine is 15 mgVtablet and thereof.
9) (Amended) Synergistic effects of the combination of the specific compound are claimed as claim 5 wherein said Race Methionine acts as a glutathione precursor. The incorporation of methionine into tablets of paracetamol is useful for protecting against hepatic and renal toxicity.
10) ( Cancelled)

STATEMENT UNDER ARTICLE 19

Claim 1 to 10 have been amended to exclude certain part of the invention falling within basis of the opinion, reasoned statement under rule 43 bis 1 (a) (1) with regard to novelty, inventive step or industrial applicability, citation and explanations supporting such statement. These amendments should have no effect on the description or Drawing.

PCT/IN2011/000867 2010-12-30 2011-12-19 Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases WO2012090218A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3568/MUM/2010 2010-12-30
IN3568MU2010 2010-12-30

Publications (2)

Publication Number Publication Date
WO2012090218A1 WO2012090218A1 (en) 2012-07-05
WO2012090218A4 true WO2012090218A4 (en) 2012-08-23

Family

ID=45607327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000867 WO2012090218A1 (en) 2010-12-30 2011-12-19 Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases

Country Status (1)

Country Link
WO (1) WO2012090218A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120021A1 (en) * 2013-02-04 2014-08-07 Aft Pharmaceuticals Limited A combination medicament comprising phenylephrine and paracetamol
GB2510444B (en) * 2013-02-04 2017-03-22 Aft Pharmaceuticals Ltd Combination of phenylephrine and paracetamol
CN108186579A (en) * 2018-02-01 2018-06-22 重庆希尔安药业有限公司 Xiao ' er Anfen Huangnamin composition grain and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114344A (en) 1998-07-16 2000-09-05 Aryx Therapeutics Long-acting local anesthetics
DE10300323A1 (en) 2003-01-09 2004-10-14 Baxter Healthcare S.A. Safety container filled with a biologically active substance, especially a cytostatic agent, is at least partially coated
US20040259809A1 (en) 2003-06-17 2004-12-23 Pediamed Pharmaceuticals, Inc. Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof
KR100681660B1 (en) 2004-03-17 2007-02-09 주식회사종근당 Pharmaceutical pellet compositions for controlled release
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
US9155703B2 (en) 2007-03-12 2015-10-13 Board Of Regents, The University Of Texas System Method and process for the production of multi-coated recognitive and releasing systems
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2010029545A2 (en) 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s. pneumoniae infection
EP2198859A1 (en) 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release

Also Published As

Publication number Publication date
WO2012090218A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
WO2007002597A3 (en) Modified-release formulations of a bupropion salt
MX2011011178A (en) Diacylethylenediamine compound.
AR124500A2 (en) INCREASED BIOAVAILABILITY OF THE DRUG IN NALTREXONE THERAPY
WO2008149802A1 (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
MX2009008084A (en) 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors.
BRPI0418681A (en) a dietary supplement for the treatment and prevention of diseases of the digestive system and diseases related to the digestive system and method of production and administration thereof.
WO2011045732A3 (en) A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity
WO2012090218A4 (en) Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases
WO2008108285A1 (en) Peptide
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
Peckham et al. Call for increased pharmacovigilance of gabapentin
MX2007002941A (en) Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy.
WO2009035253A3 (en) Novel use of scoparone
WO2007071721A3 (en) Ginger extract for inhibiting human drug transporters
WO2007144889A3 (en) Treatment of neurofibromatosis
EP2101809A4 (en) Pharmaceutical composition containing arazyme for the prevention of liver dysfunction
RU2007104920A (en) METHOD FOR REDUCING TOXIC LIVER INJURY
TH100706B (en) Composition that makes up tablets containing atazanavir.
TH100706A (en) Composition that makes up tablets containing atazanavir.
TH127960B (en) Composition that makes up tablets containing atazanavir.
TH127960A (en) Composition that makes up tablets containing atazanavir.
Akpinar Fluoxetine overdose
Hill Clarithromycin/simvastatin interaction
WO2007009706A3 (en) Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
WO2009038092A1 (en) Anti-fatigue agent comprising arachidonic acid as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817542

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11817542

Country of ref document: EP

Kind code of ref document: A1